Trial Profile
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Sep 2017
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Coronary artery disease
- Focus Biomarker; Pharmacodynamics
- Acronyms RAND-CFR
- 30 Aug 2017 Results (n=16) assessing effect of ranolazine on T wave heterogeneity presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 30 Aug 2017 Results (n=31) assessing marked exercise induced T-wave heterogeneity in diabetic patients with non-flow limiting coronary artery stenosis and impaired coronary flow reserve, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 25 Aug 2016 Status changed from active, no longer recruiting to completed.